Fertility-preserving treatment in three cases of placental site trophoblastic tumor

Placental site trophoblastic tumor (PSTT) is a rare variant of gestational trophoblastic disease. Fertility-sparing therapy for affected women, especially for those whose lesions are hypervascular of childbearing age is a challenge. The authors therefore decided to investigate the methods of fertility-sparing therapy for patients with PSTT. The cases of three patients with PSTT are presently described. All presented with disease confined to the uterus, and the lesions were hypervascular. Two patients underwent dilatation and curettage, and combined etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine/oncovin (EMA/CO) chemotherapy. One patient underwent hysteroscopic resection and EMA/CO chemotherapy. All patients underwent ultrasonography postoperatively to reevaluate the size of the lesion. The patients retained their reproductive function with no serious hemorrhage noted. The authors believe that patients with PSTT may be candidates for conservative therapy, even if the lesion is hypervascular. The sonographic presentation is important in deciding the treatment for affected patients.

Placental site trophoblastic tumor; Fertility-sparing treatment; EMA/CO; Indications; Hypervascular.

[1] Zhao J., Lv WG., Feng FZ., Wan XR., Liu JH., Yi XF., et al.: “Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment”. Gynecol. Oncol., 2016, 142, 102.

[2] Horowitz NS., Goldstein DP., Berkowitz RS: “Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities”. Gynecol Oncol., 2017, 144, 208.

[3] Schmid P., Nagai Y., Agarwal R., Hancock B., Savage PM., Sebire NJ., et al.: “Prognostic markers and long-term outcome of placentalsite trophoblastic tumours: a retrospective observational study”. Lancet, 2009, 374, 48.

[4] Tempfer C., Horn LC., Ackermann S., Beckmann MW., Dittrich R., Einenkel J., et al.: “Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015)” . Geburtshilfe Frauenheilkd., 2016, 76, 134.

[5] Huang F., Zheng W., Liang Q., Yin T: “Diagnosis and treatment of placental site trophoblastic tumor”. Int. J. Clin. Exp. Pathol., 2013, 6, 1448.

[6] Zhou Y., Lu H., Yu C., Tian Q., Lu W: “Sonographic characteristics of placental site trophoblastic tumor”. Ultrasound Obstet. Gynecol., 2013, 41, 679.

[7] Behtash N., Karimi Zarchi M: “Placental site trophoblastic tumor”. J. Cancer Res. Clin. Oncol., 2008, 134, 1.

[8] Pfeffer PE., Sebire N., Lindsay I., McIndoe A., Lim A., Seckl MJ: “Fertility-sparing partial hysterectomy for placental-site trophoblastic tumour”. Lancet Oncol., 2007, 8, 744.

[9] Machtinger R., Gotlieb WH., Korach J., Fridman E., Apter S., Goldenberg M., et al.: “Placental site trophoblastic tumor: outcome of five cases including fertility preserving management”. Gynecol Oncol., 2005, 96, 56.

[10] Taylor JS., Viera L., Caputo TA., Chan J., Frey MK., Gupta D., et al.: “Unsuccessful planned conservative resection of placental site trophoblastic tumor”. Obstet Gynecol., 2013, 121, 465.

[11] Shen X., Xiang Y., Guo L., Feng F., Wan X., Xiao Y., et al.: “Fertility- preserving treatment in young patients with placental site trophoblastic tumors”. Int. J. Gynecol Cancer, 2012, 22, 869.

[12] Zheng Y., Bao L., Ning Y., Lu X., Hua K., Yi X: “Retrospective analysis of the clinicopathologic and prognostic characteristics of stage I placental site trophoblastic tumor in China”. Int. J. Gynaecol. Obstet., 2015, 129, 67